USA - NASDAQ:DMTK - US24984K1051 - Common Stock
Taking everything into account, DMTK scores 2 out of 10 in our fundamental rating. DMTK was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of DMTK have multiple concerns. DMTK is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.51% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.44 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.46 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.094
-0.01 (-11.32%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.08 | ||
| P/tB | 0.08 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.51% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.7% | ||
| Cap/Sales | 0.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | -8.44 |
ChartMill assigns a fundamental rating of 2 / 10 to DMTK.
ChartMill assigns a valuation rating of 0 / 10 to DERMTECH INC (DMTK). This can be considered as Overvalued.
DERMTECH INC (DMTK) has a profitability rating of 1 / 10.
The financial health rating of DERMTECH INC (DMTK) is 3 / 10.
The Earnings per Share (EPS) of DERMTECH INC (DMTK) is expected to grow by 35.19% in the next year.